Abstract 608P
Background
Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma arising from mucosal surfaces. While MMs are distinct from cutaneous melanomas (CMs) in pathogenesis, etiology and prognosis, management of both subtypes has remained largely similar, as the rarity of the disease poses a challenge to developing evidence-based clinical guidelines for MM. We performed a meta-analysis on the use of immune checkpoint inhibitors (ICIs) and targeted therapy for MM.
Methods
We searched five databases (PubMed, Cochrane, Embase, Web of Science and Google Scholar) for studies evaluating the efficacy of ICIs and targeted therapy in the treatment of locally advanced or metastatic MMs. After including only cohort and observational studies with available overall survival (OS) and progression free survival (PFS) data, the eligible studies comprised patients treated with anti-PD1, anti-CTLA4, VEGFR inhibitors or tyrosine kinase inhibitors (TKIs). For single-arm and double-arm studies that reported Kaplan-Meier curves, we digitally reconstructed individual patient data using Guyot's algorithm and calculated the OS, PFS and hazard ratios, along with the 95% confidence intervals.
Results
We included 26 studies with a total of 1911 participants. Our results show that combined anti-PD1 and anti-CTLA4 therapy had the highest 12-month OS and 12-month PFS at 0.677 (0.608,0.754) and 0.388 (0.316,0.475) respectively. This was followed by anti-PD1 therapy alone (OS: 0.602 (0.569,0.638); PFS: 0.282 (0.251,0.317)), anti-PD1 and VEGFR inhibitor combination therapy (OS: 0.506 (0.437,0.585)), TKI therapy (OS: 0.482 (0.376,0.618); PFS: 0.083 (0.037,0.187)) and anti-CTLA4 therapy alone (OS: 0.333 (0.284,0.391); PFS: 0.098 (0.059,0.165)). In the double-arm studies, anti-PD1 and anti-CTLA4 combination therapy had similar OS and PFS with anti-PD1 treatment alone (OS: HR 0.866 (0.616,1.22); PFS: HR 0.848 (0.666,1.08)), however, anti-PD1 therapy alone had significantly better PFS than anti-CTLA4 alone (HR 0.548 (0.376,0.799)).
Conclusions
Collectively, these results demonstrate that anti-PD1 and anti-CTLA4 combination therapy has the most favorable outcome in the treatment of MM, while anti-PD1 therapy is the single best agent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract